Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca’s OIC product clears efficacy hurdle

This article was originally published in Scrip

Executive Summary

AstraZeneca’s two Phase III trials of the pegylated peripherally acting mu opioid receptor antagonist naloxegol (pegylated naloxol) have hit their primary endpoints in patients with non-cancer related pain and opioid-induced constipation (OIC), top-line data show. But the good news for the product has been a little overshadowed by analysts’ fears over how high regulators will place the cardiovascular safety bar for drugs for this particular indication.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC019425

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel